UK Markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.9550-0.0250 (-0.63%)
As of 01:32PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.40
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 312.8900
52-week low 32.1900
50-day moving average 34.0426
200-day moving average 35.4598

Share statistics

Avg vol (3-month) 33.37M
Avg vol (10-day) 35.63M
Shares outstanding 5101.94M
Implied shares outstanding 6N/A
Float 877.56M
% held by insiders 10.24%
% held by institutions 1118.79%
Shares short (14 Jul 2022) 440.18M
Short ratio (14 Jul 2022) 413.42
Short % of float (14 Jul 2022) 451.93%
Short % of shares outstanding (14 Jul 2022) 439.21%
Shares short (prior month 14 Jun 2022) 438.98M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 312 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin -258.35%
Operating margin (ttm)-254.65%

Management effectiveness

Return on assets (ttm)-48.88%
Return on equity (ttm)-210.70%

Income statement

Revenue (ttm)89.78M
Revenue per share (ttm)0.89
Quarterly revenue growth (yoy)17.20%
Gross profit (ttm)-90.5M
EBITDA -225.63M
Net income avi to common (ttm)-231.96M
Diluted EPS (ttm)-2.5040
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)111.91M
Total cash per share (mrq)1.09
Total debt (mrq)159.01M
Total debt/equity (mrq)663.69
Current ratio (mrq)2.39
Book value per share (mrq)2.59

Cash flow statement

Operating cash flow (ttm)-205.36M
Levered free cash flow (ttm)-102.33M